0.195
0.01 (2.63%)
| Penutupan Terdahulu | 0.190 |
| Buka | 0.190 |
| Jumlah Dagangan | 91,249 |
| Purata Dagangan (3B) | 469,374 |
| Modal Pasaran | 44,666,892 |
| Harga / Jualan (P/S) | 1.36 |
| Harga / Buku (P/B) | 1.66 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Aug 2024 |
| Margin Keuntungan | -37.69% |
| Margin Operasi (TTM) | -25.50% |
| EPS Cair (TTM) | -0.040 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 52.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 15.70% |
| Nisbah Semasa (MRQ) | 2.60 |
| Aliran Tunai Operasi (OCF TTM) | -7.86 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -4.92 M |
| Pulangan Atas Aset (ROA TTM) | -18.61% |
| Pulangan Atas Ekuiti (ROE TTM) | -39.49% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (AU) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | NOVA EYE FPO [EYE] | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 2.0 |
| Purata | -0.63 |
|
Nova Eye Medical Ltd is a medical technology company that develops, manufactures, and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The company's operating segment include AlphaRET and Glaucoma Surgical Devices, it generates maximum revenue from Glaucoma Surgical Devices. Geographically, it derives a majority of its revenue from the United States of America. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 18.59% |
| % Dimiliki oleh Institusi | 18.75% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |